Tobacco addiction and pharmacogenetics of nicotine metabolism

Journal of Neurogenetics

Volumn 23, Issue 3, 2009, Pages 262-271

  Swan, Gary E ^a   Lessov Schlaggar, Christina N ^b  

^a SRI INTERNATIONAL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dependence; Metabolism; Nicotine; Pharmacogenetics; Twins

Indexed keywords

AMFEBUTAMONE; NICOTINE;

CLINICAL TRIAL; CYP2A6 GENE; DRUG RESPONSE; ENVIRONMENTAL FACTOR; GENE; GENETIC VARIABILITY; GENOMICS; GENOTYPE; HEREDITY; HUMAN; INCIDENCE; METABOLISM; PHARMACOGENETICS; PREVALENCE; PRIORITY JOURNAL; REVIEW; SMOKING; SMOKING CESSATION; TOBACCO DEPENDENCE;

ARYL HYDROCARBON HYDROXYLASES; ENVIRONMENT; GENETIC ASSOCIATION STUDIES; HUMANS; NICOTINE; PHARMACOGENETICS; SMOKING; SMOKING CESSATION; TOBACCO USE DISORDER; TWIN STUDIES AS TOPIC; UNITED STATES;

NICOTIANA TABACUM;

EID: 68649110950     PISSN: 01677063     EISSN: 15635260     Source Type: Journal    
DOI: 10.1080/01677060802572903     Document Type: Review

References (74)

1. Amos, C. I., Wu, X., Broderick, P., Gorlov, I. P., Gu, J., Eisen, T., et al. (2008). Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Gen, 40, 616-622. (Pubitemid 351601203)
2. Aubin, H. J., Bobak, A., Britton, J. R., Oncken, C., Billing, C. B. Jr., Gong, J., et al. (2008). Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax, 63, 717-724.
3. Benowitz, N. L., & Jacob, P., III. (1997). Individual differences in nicotine kinetics and metabolism in man. In: Rapaka, R. S., Chiang, N., & Martin, B. R. (Eds.), Pharmacokinetics, Metabolism, and Pharmaceutics of Drugs of Abuse (pp. 48-64). United States Department of Health and Human Services: National Institute on Drug Abuse, Bethesda, MD, USA.
4. Benowitz, N. L., Lessov, C. N., Swan, G. E., & Jacob, P., III. (2006a). Female sex and oral contraceptive use accelerate nicotine metabolism. Clin Pharmacol Ther, 79, 480-488.
5. Benowitz, N. L., Swan, G. E., Jacob, P., III, Lessov-Schlaggar, C. N., & Tyndale, R. F. (2006b). CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. Clin Pharmacol Ther, 80, 457-467. (Pubitemid 44767882)
6. Benowitz, N. L., Lessov-Schlaggar, C. N., & Swan, G. E. (2008). Genetic influences in the variation in renal clearance of nicotine and cotinine. Clin PharmacolTher, 84, 243-247.
7. Berrettini, W., Yuan, X., Tozzi, F., Song, K., Francks, C., Chilcoat, H., et al. (2008). Alpha-5/alpha-3 nicotinic receptor subunit alleles increase risk for heavy smoking. Mol Psychiatry, 13, 368-373.
8. Bierut, L. J., Madden, P. A. F., Breslau, N., Johnson, E. O., Hatsukami, D., Pomerleau, O. F., et al. (2007). Novel genes identified in a high density genome-wide association study for nicotine dependence. Hum Mol Genet, 16, 24-35. (Pubitemid 46152542)
9. Bierut, L. J., Stitzel, J. A., Wang, J. C., Hinrichs, A. L., Bertelsen, S., Fox, L., et al..(in press). An amino acid change in the alpha 5 nicotinic receptor increases risk for nicotine dependence. Am J Psychiatry.
10. Cascorbi, H. F., Vesell, E. S., Blake, D. A., & Helrich, M. (1971). Genetic and environmental influence on halothane in twins. Clin Pharmacol Ther, 12, 50-55.
11. Chanock, S. J., & Hunter, D. J. (2008). Genomics: when the smoke clears. Nature, 452, 537-538.
12. David, S. P., Brown, R. A., Papandonatos, G. D., Kahler, C. W., Lloyd-Richardson, E. E., Munafò, M. R., et al. (2007). Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine Tobacco Res, 9, 821-833.
13. Dorus, E., Pandey, G. N., & Davis, J. M. (1975). Genetic determinants of lithium ion distribution. Arch Gen Psychiatry, 32, 1097-1102.
14. Evans, W. E., & Johnson, J. A. (2001). Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet, 2, 9-39. (Pubitemid 35264999)
15. Evans, W. E., & Relling, M. (1999). Pharmacogenomics: translating functional genomics into rational therapeutics. Science, 286, 487-491.
16. Frueh, F. W. (2006). Pharmacogenomics: patient selection for clinical trial participation and enrichment strategies. Available at: http://www.fda.gov/cder/genomics/presentations. htm. Accessed on August 12, 2008.
17. Grassi, G., Seravalle, G., Calhoun, D. A., Bolla, G. B., Giannattasio, C., Marabini, M., et al. (1994). Mechanisms responsible for sympathetic activation by cigarette smoking in humans. Circulation, 90, 248-253. (Pubitemid 24203687)
18. Hart, M. N., Wang, S., Nakamoto, K., Wesselman, C., Li, Y., & Zhong, X. (2008). Genetic polymorphisms in cytochrome P450 oxidoreductase infleunce microsomal P450-catalyzed drug metabolism. Pharmacogenet Genomics, 18, 11-24. (Pubitemid 351161645)
19. Heatherton, T. F., Kozlowski, L. T., Frecker, R. C., & Fagerström, K. O. (1991). The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. British Journal of Addiction, 86, 1119-1127.
20. Howard, L. A., Ahluwalia, J. S., Lin, S. K., Sellers, E. M., & Tyndale, R. F. (2003). CYP2E1*1D regulatory polymorphism: association with alcohol and nicotine dependence. Pharmacogenetics, 13, 321-328.
21. Huang, S.-M., Goodsaid, F., Rahman, A., Frueh, F., & Lesko, L. J. (2006). Application of pharmacogenomics in clinical pharmacology. Toxicol Mech Meth, 16, 89-99.
22. Hughes, J. R., Stead, L. F., & Lancaster, T. (2007). Anti-depressants for smoking cessation. Cochrane Database Syst Rev, CD000031.
23. Hung, R. J., McKay, J. D., Gaborieau, V., Boffetta, P., Hashibe, M., Zaridze, D., et al. (2008). A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature, 452, 633-637.
24. Hukkanen, J., Jacob, P., III, & Benowitz, N. L. (2005). Metabolism and disposition kinetics of nicotine. Pharmacol Rev, 57, 79-115.
25. Itoh, M., Nakajima, M., Higashi, E., Yoshida, R., Nagata, K., Yamazoe, Y., et al. (2006). Induction of human CYP2A6 is mediated by the pregnane X receptor with peroxisome proliferator-activated receptor-gamma coactivator 1alpha. J Pharmacol Exp Ther, 319, 693-702. (Pubitemid 44776373)
26. Javitz, H. S., Swan, G. E., Zbikowski, S. M., et al. (2004a). Cost-effectiveness of different combinations of bupropion SR dose and behavioral treatment for smoking cessation: a societal perspective. Am J Manag Care, 10, 217-226. (Pubitemid 38380779)
27. Javitz, H. S., Swan, G. E., Zbikowski, S. M., et al. (2004b). Return on investment of different combinations of bupropion SR dose and behavioral treatment for smoking cessation in a health care setting: an employer's perspective. Value Health, 7, 535-543. (Pubitemid 39390834)
28. Lerman, C., Shields, P. G., Wileyto, E. P., Audrain, J., Hawk, L. H., Jr., Pinto, A., et al. (2003). Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol, 22, 541-548. (Pubitemid 37243689)
29. Lerman, C., Tyndale, R., Patterson, F., Wileyto, E. P., Shields, P. G., Pinto, A., et al. (2006). Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin Pharmacol Ther, 79, 600-608. (Pubitemid 43817942)
30. Lessov-Schlaggar, C. N., Pergadia, M. L., Khroyan, T. V., & Swan, G. E. (2008). Genetics of nicotine dependence and pharmacotherapy. Biochem Pharmacol, 75, 178-195.
31. Li, G. H., Faulhaber, H. D., Rosenthal, M., Schuster, H., Jordan, J., Timmermann, B., et al. (2001). Beta-2 adrenergic receptor gene variations and blood pressure under stress in normal twins. Psychophysiology, 38, 485-489. (Pubitemid 32422292)
32. Malaiyandi, V., Goodz, S. D., Sellers, E. M., & Tyndale, R. F. (2006). CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking. Cancer Epidemiol Biomarkers Prev, 15, 1812-1819. (Pubitemid 44664253)
33. Mathers, C. D., & Loncar, D. (2006). Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med, 3, 2011-2030.
34. McCaffery, J. M., Pogue-Geile, M. F., Ferrell, R. E., Petro, N., & Manuck, S. B. (2002). Variability within alpha- and beta-adrenoreceptor genes as a predictor of cardiovascular function at rest and in response to mental challenge. J Hypertens, 20, 1105-1114. (Pubitemid 34913628)
35. McCaffery, J. M., Bleil, M., Pogue-Geile, M. F., Ferrell, R. E., & Manuck, S. B. (2003). Allelic variation in the serotonin transporter gene-linked polymorphic region (5-HTTLPR) and cardiovascular reactivity in young adult male and female twins of European-American descent. Psychosom Med, 65, 721-728. (Pubitemid 37163375)
36. McClure, J., & Swan, G. E. (2006). Tailoring nicotine replacement therapy: rationale and potential approaches. CNS Drugs, 20, 281-291.
37. Meyer, U. A. (2004). Pharmacogenetics - five decades of therapeutic lessons from genetic diversity. Nat Rev Genet, 5, 669-676.
38. Moolchan, E. T., Hudson, D. L., Schroeder, J. R., & Sehnert, S. S. (2004). Heart rate and blood pressure responses to tobacco smoking among African-American adolescents. J Natl Med Assoc, 96, 767-771. (Pubitemid 38745784)
39. Mwenifumbo, J. C., Lessov-Schlaggar, C. N., Zhou, Q., Krassnow, R. E., Swan, G. E., Benowitz, N. L., et al. (2008). Identification of novel CYP2A6*1B variants; the CYP2A6*1B allele is associated with faster in vivo nicotine metabolism. Clin Pharmacol Ther, 83, 115-121.
40. Nakajima, M., Tanaka, E., Kwon, J. T., & Yokoi, T. (2002). Characterization of nicotine and cotinine N-glucuronidations in human liver microsomes. Drug Metab Dispos, 30, 1484-1490. (Pubitemid 35397057)
41. Neale, M. C., & Cardon, L. (1992). Methodology for Genetic Studies of Twins and Families. Dordect/Boston/London: Kluwer Academic Publishers.
42. Neale, M. C., Boker, S. M., Xie, G., & Maes, H. H. (2002). Mx: Statistical Modeling, 6th ed. Richmond, Virginia, USA: Department of Psychiatry, Virginia Commonwealth University.
43. Niaura, R., Shadel, W. G., Goldstein, M. G., Hutchinson, K. E., & Abrams, D. B. (2001). Individual differences in responses to the first cigarette following overnight abstinence in regular smokers. Nicotine Tobacco Res, 3, 37-44. (Pubitemid 32611537)
44. O'Loughlin, J., Paradis, G., Kim, W., DiFranza, J., Meshefedjian, G., McMillan-Davey, E., et al. (2004). Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study of novice smokers. Tobacco Contr, 13, 422-428. (Pubitemid 39635932)
45. Pomerleau, O. F., Collins, A. C., Shiffman, S., & Pomerleau, C. S. (1993). Why some people smoke and others do not: new perspectives. J Consult Clin Psychol, 61, 723-731. (Pubitemid 23304584)
46. Rieder, M. J., Reiner, A. P., Gage, B. F., Nickerson, D. A., Eby, C. S., McLeod, H. L., et al. (2005). Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med, 352, 2285-2293.
47. Rubin, D. (2002). PharmGKB: The Pharmacogenetics Knowledge Base. Available at: http://infolab.stanford.edu/infoseminar/Archive/WinterY2002/rubin. pdf. Accessed on August 12, 2008.
48. Saccone, S. F., Hinrichs, A. L., Saccone, N. L., Chase, G. A., Konvicka, K., Madden, P. A. F., et al. (2007). Cholinergic nicotinic receptor genes implicated in a nicotine-dependence association study targeting 348 candidate genes with 3,713 SNPs. Hum Mol Genet,16, 36-49. (Pubitemid 46152543)
49. SAS Institute, SAS for Windows, version 9.1. Cary, North Carolina, USA: SAS Institute, Inc., copyright 2002-2003.
50. Silagy, C., Lancaster, T., Stead, L., Mant, D., & Fowler, G. (2004). Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev, CD000146.
51. Snieder, H., Harshfield, G. A., Barbeau, P., Pollock, D. M., Pollock, J. S., & Treiber, F. A. (2002). Dissecting the genetic architecture of the cardiovascular and renal stress response. Biolog Psychol, 61, 73-95. (Pubitemid 35248149)
52. Stolerman, I. P., & Jarvis, M. J. (1995). The scientific case that nicotine is addictive. Psychopharmacology, 117, 2-10.
53. Swan, G. E., Jack, L. M., & Ward, M. M. (1997). Subgroups of smokers with different success rates after use of transdermal nicotine. Addiction, 92, 207-218.
54. Swan, G. E., Benowitz, N. L., Jacob, P., III, Lessov, C. N., Tyndale, R. F., Wilhelmsen, K., et al. (2004). Pharmacogenetics of nicotine metabolism in twins: methods and procedures. Twin Res, 7, 435-448. (Pubitemid 39390138)
55. Swan, G. E., Benowitz, N. L., Lessov, C. N., Jacob, P., III, Tyndale, R. F., & Wilhelmsen, K. (2005a). Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence. Pharmacogenet Genomics, 15, 115-125.
56. Swan, G. E., Valdes, A. M., Ring, H. Z., Khroyan, T. V., Jack, L. M., Ton, C. C., et al. (2005b). Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR. Pharmacogenomics J, 5, 21-29.
57. Swan, G. E., Hops, H., Wilhelmsen, K. C., Lessov, C. N., Cheng, L.S-C., Hudmon, K. S., et al. (2006). A genomewide screen for nicotine dependence susceptibility loci. Am J Med Genet B Neuropsychiatric Genet, 141, 354-360. (Pubitemid 43872886)
58. Swan, G. E., Jack, L. M., Valdes, A. M., Ring, H. Z., Ton, C. C., Curry, S. J., et al. (2007a). Joint effect of dopaminergic genes on likelihood of smoking following treatment with bupropion SR. Health Psychol, 26, 361-368.
59. Swan, G. E., Lessov-Schlaggar, C. N., Krasnow, R. E., Wilhelmsen, K. C., Jacob, P., III, & Benowitz, N. L. (2007b). Genetic and environmental sources of variation in heart rate response to infused nicotine in twins. Cancer Epidemiol Biomarkers Prev, 16, 1057-1064.
60. Swan, G. E., Jack, L. M., Javitz, H., McAfee, T., & McClure, J. M. (2008). Predictors of 12-month outcome in smokers who received bupropion SR for smoking cessation. CNS Drugs, 22, 239-256. (Pubitemid 351263726)
61. Swan, G. E., Lessov-Schlaggar, C. N., Bergen A. W., He, Y., Tyndale, R. F., & Benowitz, N. L. (in press). Genetic and environmental influences on the ratio of 3′hydroxycotinine to cotinine in plasma and urine. Pharmacogenet Genomics.
62. Thorgeirsson, T. E., Geller, F., Sulem, P., Rafnar, T., Wiste, A., Magnusson, K. P., et al. (2008). Variant associated with nicotine dependence, lung cancer, and peripheral arterial disease. Nature, 452, 638-642.
63. Uhl, G. R., Drgon, T., Johnson, C., Fatusin, O. O., Liu, Q. R., Contoreggi, C., et al. (2008a). "Higher order" addiction molecular genetics: convergent data from genomewide association in humans and mice. Biochem Pharmacol, 75, 98-111.
64. Uhl, G. R., Liu, Q. R., Drgon, T., Johnson, C., Walther, D., Rose, J. E., et al. (2008b). Molecular genetics of successful smoking cessation: convergent genomewide association study results. Arch Gen Psychiatry, 65, 683-693. (Pubitemid 351787239)
65. Vesell, E. S., Page, J. G., & Passanti, T. G. (1971). Genetic and environmental factors affecting ethanol metabolism in man. Clin Pharmacol Ther, 12, 192-201.
66. Vesell, E. S. (1981). The influence of host factors on drug response. VII. Implications for interpretation of clinical trials and other published studies on drug response in man. Rational Drug Ther, 15, 1-5.
67. Weber, W. W. (1997). Pharmacogenetics. New York: Oxford University Press.
68. Weinshilboum, R. M., & Wang, L. (2006). Pharmacogenetics and pharmacogenomics: development, science, and translation. Annu Rev Genomics Human Genet, 7, 223-245.
69. Williams, R. B., Marchuk, D. A., Gadde, K. M., Barefoot, J. C., Grichnik, K., Helms, M. J., et al. (2001). Central nervous system serotonin function and cardiovascular responses to stress. Psychosom Med, 63, 300-305. (Pubitemid 32249955)
70. World Health Organization. The Tobacco Atlas. 2002. Available at: http://www.who.int/tobacco/statistics/tobacco-atlas. Accessed on December 17, 2008.
71. Yamanaka, H., Nakajima, M., Fukami, T., Sakai, H., Nakamura, A., Katoh, M., et al. (2005). CYP2A6 and CYP2B6 are involved in nornicotine formation from nicotine in humans: interindividual differences in these contributions. Drug Metab Dispos, 33, 1811-1818. (Pubitemid 41697266)
72. Yin, T., & Miyata, T. (2007). Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives. Thromb Res, 120, 1-10. (Pubitemid 46601582)
73. Zevin, S., Schaner, M. E., & Giacomini, K. M. (1998). Nicotine transport in a human choriocarcinoma cell line (JAR). J Pharmaceut Sci, 87, 702-706. (Pubitemid 28268568)
74. Zhang, L., Rao, F., Wessel, J., Kennedy, B. P., Rana, B. K., Taupenot, L., et al.. (2004). Functional allelic heterogeneity and pleiotropy of a repeat polymorphism in tyrosine hydroxylase: prediction of catecholamines and response to stress in twins. Physiolog Genomics, 19, 277-291.